Drugs / Targeting CD276 CAR T cells
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 0 | NCT04864821 | May 2021 → May 2022 | gastric cancer, lung cancer, neuroblastoma, osteosarcoma | PersonGen BioTherapeutics (Suzhou) Co., Ltd. | Unknown | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Targeting CD276 CAR T cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04864821 ↗ |
| Modality | Cell therapy | “Targeting CD276 autologous chimeric antigen receptor T cells” NCT04864821 ↗ |
| Route | Intravenous | “by intravenous and local tumor injection” NCT04864821 ↗ |
| Route | Other | “by intravenous and local tumor injection” NCT04864821 ↗ |
| Target | CD276 | “Targeting CD276 autologous chimeric antigen receptor T cells” NCT04864821 ↗ |